{"title": "Communication to industry", "author": null, "url": "https://www.sahpra.org.za/communication-to-industry/", "hostname": "sahpra.org.za", "description": "A comprehensive library of all SAHPRA related SAHPRA .", "sitename": "SAHPRA", "date": "2022-03-07", "cleaned_text": "[Annual retention fee payment notification for the Financial year ending 31 March 2024](https://www.sahpra.org.za/document/annual-retention-fee-payment-notification-for-the-financial-year-ending-31-march-2024/) [Communication to industry](https://www.sahpra.org.za/document-category/communication-to-industry/) |08/06/2023||1|[Finance](https://www.sahpra.org.za/document-tag/finance/) |pdf|[Download](https://www.sahpra.org.za/wp-content/uploads/2023/06/Annual-retention-fee-payment-notification-for-the-Financial-year-ending-31-March-2024.pdf) |communication-to-industry||finance| |02/06/2023||1|[Complementary Medicines](https://www.sahpra.org.za/document-tag/complementary-medicines/) |pdf|[Download](https://www.sahpra.org.za/wp-content/uploads/2023/06/Communication-Industry-on-the-Regulation-of-Category-D-Medicines-02-June-2023.pdf) |communication-to-industry||complementary-medicines| [Communication to industry](https://www.sahpra.org.za/document-category/communication-to-industry/) |02/06/2023||1|[Pharmacovigilance](https://www.sahpra.org.za/document-tag/pharmacovigilance/) |pdf|[Download](https://www.sahpra.org.za/wp-content/uploads/2023/06/Medicine-Safety-Regulatory-Decisions_Issue-No.-02_2022_23.pdf) |pdf|[Download](https://www.sahpra.org.za/wp-content/uploads/2023/03/Comm-to-Industry-Verification-of-Fees-and-Bank-details-MG.pdf) |communication-to-industry||finance| |HPA-10|[Communication to SAHPRA Service Desk](https://www.sahpra.org.za/document/communication-to-industry-pilot-application-process-through-the-sahpra-service-desk/) - [Communication to Variation Screening Change Applications and TOAs](https://www.sahpra.org.za/document/certification-variation-screening-type-ii-proprietary-name-change-applications-and-toas-2/) [Communication change applications and TOA's](https://www.sahpra.org.za/document/certification-variation-screening-type-ii-proprietary-name-change-applications-and-toas/) [Communication [Position Paper Proposal to Applicants Processing Fee (ZaZiBoNa)](https://www.sahpra.org.za/document/position-paper-proposal-to-applicants-for-dossier-processing-fee-zazibona/) [Communication Section 21 Authorisation for industry](https://www.sahpra.org.za/document-category/communication-to-industry/) on Nitrosamine for New Applications and Registered Products including Biologicals](https://www.sahpra.org.za/document/communication-to-industry-on-nitrosamine-review-for-new-applications-and-registered-products-including-biologicals/) and CPP Certificates](https://www.sahpra.org.za/document/communication-to-industry-applications-for-gmp-and-cpp-certificates/) [Communication to industry](https://www.sahpra.org.za/document-category/communication-to-industry/) |30/06/2022||1|[Inspectorate and good manufacturing practices](https://www.sahpra.org.za/document-tag/inspectorate-and-good-manufacturing-practices/) |communication-to-industry||medical-devices| [Communication to Stakeholders with regards to the current status of the Medical Device industry - to industry](https://www.sahpra.org.za/document-category/communication-to-industry/) |17/03/2022||1|[Complementary Medicines](https://www.sahpra.org.za/document-tag/complementary-medicines/) |pdf|[Download](https://www.sahpra.org.za/wp-content/uploads/2022/03/Stakeholder-notice-7.04_CM_SE_Health_Supplements_Mar22_v4_3.pdf) |communication-to-industry||complementary-medicines| [Requests: [Communication [Communication to industry](https://www.sahpra.org.za/document-category/communication-to-industry/) SECTION 22C(1)(b) LICENCE (LICENCE TO CULTIVATE CANNABIS FOR THE PURPOSES OF PRODUCING SCHEDULED SUBSTANCES)](https://www.sahpra.org.za/document/gmp-certificates-for-cannabis-cultivated-by-cultivators-holding-a-section-22c1b-licence-licence-to-cultivate-cannabis-for-the-purposes-of-producing-scheduled-substances/) [Communication licencing| details for Guideline 8.04 Recall, Adverse Event And Post- Marketing Vigilance Reporting Of Medical Devices for the Importation of Research Use Only (RUO) In Vitro Diagnostic Devices (IVDs)](https://www.sahpra.org.za/document/md027-section-21-authorisation-for-the-importation-of-research-use-only-ruo-in-vitro-diagnostic-devices-ivds/) [Communication to industry](https://www.sahpra.org.za/document-category/communication-to-industry/) |12/03/2021||1|[Medical Devices](https://www.sahpra.org.za/document-tag/medical-devices/) |pdf|[Download](https://www.sahpra.org.za/wp-content/uploads/2020/09/MD025_Alternative-licensing-and-regulatory-pathway-for-masks_September2020_vF.pdf) |communication-to-industry||medical-devices| |MD025|[Licensing and Regulatory requirements for the manufacture and distribution of medical and respirator masks |communication-to-industry||complementary-medicines| [REQUESTS: Existing Category D (Complementary Medicines) Registration Applications - COMPLEMENTARY MEDICINES APPLICATIONS SUBMITTED FOR REGISTRATION](https://www.sahpra.org.za/document/requests-existing-category-d-complementary-medicines-registration-applications-complementary-medicines-applications-submitted-for-registration/) [Communication to industry](https://www.sahpra.org.za/document-category/communication-to-industry/) |27/10/2021||1|[Complementary Medicines](https://www.sahpra.org.za/document-tag/complementary-medicines/) |pdf|[Download](https://www.sahpra.org.za/wp-content/uploads/2021/10/Existing-CAT-D-CM-Applications-Memo-to-stakeholders.pdf) |communication-to-industry||complementary-medicines| [Review of detained product at a port of entry as a Category D medicine](https://www.sahpra.org.za/document/review-of-detained-product-at-a-port-of-entry-as-a-category-d-medicine/) [Communication to industry](https://www.sahpra.org.za/document-category/communication-to-industry/) |30/11/2021||1|[Complementary Medicines](https://www.sahpra.org.za/document-tag/complementary-medicines/) |pdf|[Download](https://www.sahpra.org.za/wp-content/uploads/2021/11/Review-of-detained-product-at-a-port-of-entry-as-a-Category-D-medicine.pdf) |communication-to-industry||complementary-medicines| [Application for a certificate of free sale for Category D medicines (Complementary Medicines)](https://www.sahpra.org.za/document/application-for-a-certificate-of-free-sale-for-category-d-medicines-complementary-medicines/) [Communication to industry](https://www.sahpra.org.za/document-category/communication-to-industry/) |24/11/2021||1|[Complementary Medicines](https://www.sahpra.org.za/document-tag/complementary-medicines/) |pdf|[Download](https://www.sahpra.org.za/wp-content/uploads/2021/11/Certificate-of-Free-Sale-APPLICATION-FOR-A-CERTIFICATE-OF-FREE-SALE-FOR-CATEGORY-D-MEDICINES-COMPLEMENTARY-MEDICINES.pdf) |communication-to-industry||complementary-medicines| |7.02|[updated - transitional medicines](https://www.sahpra.org.za/document/updated-roadmap-and-transitional-process-for-the-regulation-of-complementary-medicines/) [Communication to industry](https://www.sahpra.org.za/document-category/communication-to-industry/) |08/12/2021||1|[Complementary Electronic Submission of Clinical Trial Documents (Amendments, Bioequivalence Studies, Responses, Notifications, And Serious Adverse |24/06/2021||1|[Clinical Trials](https://www.sahpra.org.za/document-tag/clinical-trials/) |MD004|[Extension document on regulatory requirements for vaccines intended to provide protection against variant strain(s) "}